Biosensors International Group Ltd.

The surge in demand for angioplasty balloons and stents is mainly driven by the increasing prevalence of cardiovascular diseases (CVDs), the growing preference for minimally invasive procedures, and advancements in drug-coated/drug-eluting balloon technologies, among other factors. Moreover, the market for angioplasty balloons and stents is expected to expand due to numerous ongoing research initiatives, collaborations between healthcare entities, researchers, and industry stakeholders, as well as strategic partnerships. These elements are poised to fuel the growth of the angioplasty balloons and stents market from 2024 to 2030. LAS VEGAS, May 2, 2024 /PRNewswire/ -- DelveInsight's Angioplasty Balloons and Stents Market Insights report provides the current and forecast market analysis, individual leading angioplasty balloons and stents companies' market shares, challenges, angioplasty balloons and stents market drivers, barriers, trends, and key market angioplasty balloons and stents companies in the market. Key Takeaways from the Angioplasty Balloons and Stents Market Report As per DelveInsight estimates, North America is anticipated to dominate the global angioplasty balloons and stents market during the forecast period. Notable angioplasty balloons and stents companies such as B. Braun SE, BIOTRONIK, Medtronic, Abbott, Boston Scientific Corporation, Cook, Biosensors International Group, Ltd., MicroPort Scientific Corporation, Terumo Corporation, Demax Medical Technology, BD, BrosMed Medical Co., Ltd., Cordis, Sino Medical Sciences Technology Inc., Concept Medical, and several others, are currently operating in the angioplasty balloons and stents market. In January 2023, the FDA approved the Stellarex 0.035" OTW Drug-coated Angioplasty Balloon – P160049/S015, from Philips Image Guided Therapy Corp. In November 2022, Genesis MedTech Group announced that the FDA has approved the Chocolate Touch® Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery. In August 2019, B. Braun Interventional Systems Inc. (BIS) announced that the FDA granted Breakthrough Device Designation for the SeQuent Please ReX drug-coated PTCA balloon catheter. To read more about the latest highlights related to the angioplasty balloons and stents market, get a snapshot of the key highlights entailed in the Global Angioplasty Balloons and Stents Market Report Angioplasty Balloons and Stents Overview Angioplasty balloons and stents represent groundbreaking advancements in cardiovascular medicine, revolutionizing the treatment of coronary artery disease. Angioplasty balloons are inflatable catheters used to widen narrowed or blocked arteries by compressing the plaque against the artery walls, restoring blood flow to the heart. These balloons are typically inserted into the affected artery during a minimally invasive procedure known as percutaneous coronary intervention (PCI). By exerting controlled pressure, angioplasty balloons effectively alleviate symptoms such as chest pain and reduce the risk of heart attacks. Complementing angioplasty balloons, stents are mesh-like tubes made of metal or polymer that are deployed within the artery post-balloon inflation to provide structural support and maintain vessel patency. Stents act as scaffolding, preventing the artery from collapsing and reducing the likelihood of re-narrowing, a common complication known as restenosis. Furthermore, drug-eluting stents release medication over time to inhibit cell proliferation, further reducing the risk of restenosis. Together, angioplasty balloons and stents offer a minimally invasive, highly effective solution for restoring blood flow in diseased coronary arteries, improving patient outcomes and quality of life. Angioplasty Balloons and Stents Market Insights In 2023, North America led the angioplasty balloons and stents market, driven by increased utilization of these medical devices in treating peripheral and coronary artery diseases. This trend stems from rising sedentary lifestyles, anxiety, and stress, which contribute to conditions like diabetes and obesity, ultimately elevating the prevalence of cardiovascular diseases. Factors such as continuous product launches, regulatory support, and a surge in approvals further boost the angioplasty balloons and stents market, especially in the US. For instance, a 2023 study by the Centre for Disease Control and Prevention (CDC) revealed that in 2021, 1 in 20 adults aged 20 and above had coronary artery disease, with coronary heart disease being the leading cause of death in the US, claiming 375,476 lives in 2021. Notably, around 2 in 10 CAD-related deaths occurred in adults under 65 years old. This high disease burden underscores the necessity for drug-eluting balloons. Moreover, the American Heart Association estimated that over 500,000 percutaneous coronary intervention (PCI) procedures are performed annually in the US. The use of drug-coated balloons (DCB) in PCI procedures has emerged as an innovative approach to dilate coronary stenosis and administer anti-proliferative drugs to vessel walls, consequently driving demand for drug-eluting balloons. Additionally, the presence of major manufacturers, along with the introduction of new and advanced devices, and favorable reimbursement policies contribute significantly to the angioplasty balloons and stents market's growth. For example, in November 2022, Genesis MedTech Group received FDA approval for the Chocolate Touch® Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, to treat peripheral artery disease in the superficial femoral artery and the popliteal artery. These factors collectively indicate a promising outlook for the angioplasty balloons and stents market in North America from 2024 to 2030. To know more about why North America is leading the market growth in the angioplasty balloons and stents market, get a snapshot of the Angioplasty Balloons and Stents Market Outlook Angioplasty Balloons and Stents Market Dynamics The angioplasty balloons and stents market dynamics are heavily influenced by t echnological advancements, demographic shifts, and the prevalence of cardiovascular diseases. As medical technology continues to evolve, angioplasty balloons and stents have become increasingly sophisticated, offering improved efficacy and safety profiles. This trend drives angioplasty balloons and stents market growth as healthcare providers seek innovative solutions to address the rising burden of cardiovascular conditions globally. Moreover, the aging population contributes significantly to the expansion of the angioplasty balloons and stents market. With an increasing number of elderly individuals susceptible to cardiovascular diseases such as coronary artery disease and peripheral artery disease, the demand for minimally invasive procedures like angioplasty with stent placement continues to rise. This demographic shift amplifies the need for advanced medical devices capable of providing effective treatment while minimizing patient discomfort and recovery time. Additionally, regulatory changes and healthcare reforms play a crucial role in shaping the market dynamics of angioplasty balloons and stents. Stringent regulations regarding product safety, efficacy, and reimbursement policies influence the adoption of new technologies and angioplasty balloons and stents market entry strategies. Companies operating in this space must navigate these regulatory landscapes effectively to ensure compliance and capitalize on emerging opportunities in the ever-evolving healthcare industry. Get a sneak peek at the angioplasty balloons and stents market dynamics @ Angioplasty Balloons and Stents Market Dynamics Analysis Angioplasty Balloons and Stents Market Assessment Angioplasty Balloons and Stents Market Segmentation Angioplasty Balloons and Stents Market Segmentation By Product Type: Balloons (Drug-Coated Balloons and Plain Old Balloons), Stents (Drug-Eluting Stents and Bare Metal Stents) Angioplasty Balloons and Stents Market Segmentation By Indication: Coronary Artery Disease and Peripheral Artery Disease Angioplasty Balloons and Stents Market Segmentation By End User: Hospitals, Ambulatory Surgical Centers, and Cath Labs Angioplasty Balloons and Stents Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the angioplasty balloons and stents market are set to emerge as the trendsetter explore @ Angioplasty Balloons and Stents Companies Table of Contents Interested in knowing the angioplasty balloons and stents market by 2030? Click to get a snapshot of the Angioplasty Balloons and Stents Market Trends Related Reports Peripheral Arterial Disease Pipeline Peripheral Arterial Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key peripheral arterial disease companies, including Caladrius Biosciences, Reven Pharmaceuticals, Inc, Helixmith Co., Ltd, among others. Peripheral Artery Disease Market Peripheral Artery Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key critical limb ischemia companies, including Ixaka Ltd (formerly Rexgenero), Hemostemix Inc, Lisata Therapeutics, Caladrius Biosciences, Reven Pharmaceuticals, Inc, Helixmith Co., Ltd, among others. Critical Limb Ischemia Pipeline Critical Limb Ischemia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key critical limb ischemia companies, including Pluristem Therapeutics, Reven Pharmaceuticals, Inc., New Beta Innovation Limited, among others. Critical Limb Ischemia Market Critical Limb Ischemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key critical limb ischemia companies, including Boston Scientific Corporation, AnGes, Inc, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

NEW YORK, Oct. 20, 2023 /PRNewswire/ -- The Transcatheter Aortic Valve Replacement (TAVR) Market size is expected to increase by USD 2.34 billion, accelerating at a CAGR of 7.01% during the forecast period, according to Technavio market analysis. The report analyzes the market's competitive landscape and offers information on several market companies, including: 4C Medical Technologies Inc., Abbott Laboratories, Anteris Technologies Ltd., Artivion Inc., Biosensors International Group Ltd., Boston Scientific Corp., Colibri Heart Valve LLC, Edwards Lifesciences Corp., Genesis Medtech International Pvt. Ltd., HighLife SAS, JenaValve Technology Inc., LifeNet Health Inc., LivaNova Plc, Medinol Ltd., Medtronic Plc, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corp., Shockwave Medical Inc., Siemens AG, and Venus Medtech Hangzhou Inc. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. buy the report! Continue Reading Technavio has announced its latest market research report titled Global Transcatheter Aortic Valve Replacement Market 2023-2027 Transcatheter Aortic Valve Replacement (TAVR) Market 2023 – 2027: Company Profile: Abbott Laboratories: The company offers transcatheter aortic valve replacement, namely Navitor designed to treat aortic stenosis. To gain access to more company profiles available with Technavio, Read Free PDF Sample Report Transcatheter Aortic Valve Replacement (TAVR) Market 2023 – 2027: Geographical Analysis North America is expected to make a substantial 43% contribution to the global market's growth during the forecast period. Key factors significantly fueling the growth of the transcatheter aortic valve replacement (TAVR) market in North America include the elevated prevalence of heart-related conditions like heart valve diseases, stenosis, and atresia, the increasing adoption of suture-less valves, tissue valves, and minimally invasive procedures, and the rapid expansion of the older adult population. Transcatheter Aortic Valve Replacement (TAVR) Market 2023 – 2027: Segmentation Analysis The market is segmented by End-user (Hospitals, Ambulatory surgical centers, and Others), Type (Balloon-expanding valve and Self expanding valve), and Geography (North America, Europe, Asia, and Rest of World (ROW)). During the forecast period, substantial growth is expected in the hospital segment. This particular segment serves as the principal end-user for minimally invasive cardiac procedures, making a significant contribution to the global transcatheter aortic valve replacement (TAVR) market. Within this segment, a variety of healthcare facilities are included, ranging from prominent academic medical centers to community hospitals. These facilities have specialized infrastructure and a highly skilled medical workforce capable of performing TAVR procedures safely and effectively. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Free PDF Sample Report Transcatheter Aortic Valve Replacement (TAVR) Market 2023 – 2027: Driver & Trend: Driver Growing global aging population, with 10% over 65 years in 2022 and a projected increase to 16% by 2050. Increasing prevalence of aortic valve disease, particularly aortic stenosis, among older individuals. Extended life expectancy due to improved healthcare and living conditions. Elevated demand for transcatheter aortic valve replacement (TAVR) procedures because of these demographic shifts, positively impacting market growth during the forecast period. Trend - A key factor shaping the transcatheter aortic valve replacement market growth is the growing expansion of indications for TAVR procedures. Identify key trends, drivers, and challenges in the market. Download the free sample report now to gain access to this information Related Reports : Transcatheter Pulmonary Valve Market : The transcatheter pulmonary valve market share is expected to increase by USD 51.74 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.1%. Angio Suites Market : The angio suites market is estimated to grow at a CAGR of 5.65% between 2022 and 2027. The size of the market is forecasted to increase by USD 819.65 million. What are the key data covered in this transcatheter aortic valve replacement market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the transcatheter aortic valve replacement market between 2022 and 2027. Precise estimation of the transcatheter aortic valve replacement market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of transcatheter aortic valve replacement market vendors. TOC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by End-User Market Segmentation by Type Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

DUBLIN--( BUSINESS WIRE )--The "Bioabsorbable Stents (BAS) Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive information about the Bioabsorbable Stents (BAS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Bioabsorbable stents are also known as bioreabsorbable or biodegradable coronary stents. The advantage of this stent is that it does not leave any metal body behind and hence, the possibility of late-stent thrombosis and restenosis decreases. Bioabsorbable stents help in better drug delivery compared to metallic stents. Scope Extensive coverage of the Bioabsorbable Stents (BAS) under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment/industry Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Bioabsorbable Stents (BAS) Overview 3 Products under Development 3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory 3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies 4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development 4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 5 Bioabsorbable Stents (BAS) Companies and Product Overview 5.1 Abbott Vascular Inc Company Overview 5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 5.2 Amaranth Medical Inc Company Overview 5.3 Arterius Ltd Company Overview 5.4 Biosensors International Group Ltd Company Overview 5.5 Biosten, LLC Company Overview 5.6 Biotronik AG Company Overview 5.7 Biotronik SE & Co KG Company Overview 5.8 Biotyx Medical (Shenzhen) Co Ltd Company Overview 5.9 Boston Scientific Corp Company Overview 5.10 Cardionovum GmbH Company Overview 5.11 Cordis Corp Company Overview 5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview 5.13 Icon Interventional Systems, Inc. Company Overview 5.14 Japan Stent Technology Co., Ltd. Company Overview 5.15 Kyoto Medical Planning Co Ltd Company Overview 5.16 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 5.17 Manli Cardiology Ltd Company Overview 5.18 Meril Life Sciences Pvt Ltd Company Overview 5.19 Micell Technologies Inc Company Overview 5.20 Michigan Technological University Company Overview 5.21 MicroPort Scientific Corp Company Overview 5.22 Minvasys SAS Company Overview 5.23 MIV Therapeutics Inc Company Overview 5.24 NanoCoeur, Inc. Company Overview 5.25 North Carolina State University Company Overview 5.26 Northwestern University Company Overview 5.27 OrbusNeich Company Overview 5.28 Pediastent LLC Company Overview 5.29 QualiMed Innovative Medizinprodukte GmbH Company Overview 5.30 REVA Medical Inc Company Overview 5.31 S3V Vascular Technologies Company Overview 5.32 Shanghai Bio-heart Biological Technology Co Ltd Company Overview 5.33 Shanghai Healing Medical Instruments Co Ltd Company Overview 5.34 Tepha Inc Company Overview 5.35 Tremedics Medical Devices LLC Company Overview 5.36 UAB Minority Health and Health Equity Research Center Company Overview 5.37 University of Florida Company Overview 5.38 University of Strathclyde Company Overview 5.39 VasoTech Inc. Company Overview 5.40 Xenogenics Corporation Company Overview 6 Bioabsorbable Stents (BAS)- Recent Developments 6.1 Mar 08, 2023: OrbusNeich Announces Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million 6.2 Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023 6.3 Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022 6.4 Nov 10, 2022: Terumo Corp Announces Consolidated Financial Results for the Second Quarter Ended September 30, 2022 6.5 Aug 16, 2022: Boston Scientific Announces Upcoming Conference Schedule 6.6 Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022 6.7 Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022 7 Appendix For more information about this report visit https://www.researchandmarkets.com/r/d7bf3z About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.